Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04819841 · ClinicalTrials.gov registry record · Phase 1
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease, sponsored by Kamau Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT04819841 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by Kamau Therapeutics. The registered enrollment target is 15 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04819841, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Kamau Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Conditions Studied
Interventions
- GENETIC nula-cel Drug Product
Study Locations (4)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital - Palo Alto
Missouri
- Washington University - St Louis
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04819841
The ClinicalTrials.gov registry entry for NCT04819841 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (95% lower). The listed sponsor is Kamau Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which nula-cel Drug Product is the first listed.
NCT04819841 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT04819841 about?
NCT04819841 is a clinical study titled "Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease". This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynami...
What is the current status of trial NCT04819841?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-11-15. Estimated completion is 2028-12-31.
What conditions does trial NCT04819841 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04819841?
The interventions under investigation include: nula-cel Drug Product (GENETIC).
Who is sponsoring clinical trial NCT04819841?
This trial is sponsored by Kamau Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04819841 being conducted?
This trial has 4 study locations across California, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
-
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.